BioTissue Presents Advancements in Dry Eye Disease Treatment at Academy 2023

Pioneering Cryopreserved Amniotic Membrane Therapy Shown to Significantly Improve Patient Well-Being, Reinforcing Commitment to Elevating Ocular Care Standards

MIAMI, October 10, 2023—Findings of a new multi-center, retrospective study conducted on patients with moderate to severe Dry Eye Disease (DED) treated with BioTissue’s self-retained Prokera^® Slim Amniotic Membrane corneal bandage show significantly improved patient outcomes in less time. The research will be presented in a poster at the American Academy of Optometry 2023 meeting this week in New Orleans.

“The findings presented highlight the progress we’ve made in enhancing treatment options for individuals affected by DED, further emphasizing our focus on empowering healthcare professionals to elevate the standards of care and make a positive difference in the lives of their patients,” said BioTissue CEO Ted Davis.

The poster, Sutureless Cryopreserved Amniotic Membrane for Moderate to Severe Dry Eye with Short Treatment Duration by Damon Dierker, OD, FAAO, et al., reexamines the traditional five-to-seven-day treatment duration for sutureless Cryopreserved Amniotic Membrane in addressing DED. In the study, nine patients were treated with Prokera Slim for just two days and were observed at one-week, one-month, and three-month time intervals.

The main result of the study revealed a significant improvement in Dry Eye Workshop (DEWS) scores one-week, one-month, and three-months post-treatment. Baseline scores improved from 3.1 +/- 0.6 at baseline to 1.50 +/- 0.5 at one-week (p=0.006) and 1.2 +/- 0.4 at both one- and three-months (p=0.004) with no reported complications or adverse effects throughout the study. This underscores the significant relief provided by Prokera Slim and the enhancement of clinical signs in DED for a duration of up to three-months.

“This study has allowed us the opportunity to reexamine the conventional approach to treating moderate to severe DED by significantly decreasing the required treatment duration for patients,” said Dr. Dierker. “Administering Prokera Slim for just two days and seeing substantial improvements over a three-month period emphasizes the potential for shorter, more efficient treatments in the future.”

The poster (#59) will be presented on Thursday, October 12, in Exhibit Hall D from 4:30 p.m. to 6:30 p.m.

About BioTissue Holdings Inc.

BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues Biologics License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 800,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.

Media Contact

Laura DiCaprio

McDougall Communications for BioTissue

[email protected] or (585) 434-2153